Covalon Technologies Ltd.

Equities

COV

CA22282D3022

Biotechnology & Medical Research

Market Closed - Toronto S.E. Other stock markets 12:31:12 17/05/2024 am IST			5-day change	1st Jan Change
1.09 ^CAD	-1.80%		0.00%	+2.83%

06/03	Transcript : Covalon Technologies Ltd. - Shareholder/Analyst Call
28/02	Covalon Technologies Ltd. Reports Earnings Results for the First Quarter Ended December 31, 2023	CI

Tranche Update on Covalon Technologies Ltd.'s Equity Buyback Plan announced on May 25, 2022.

August 16, 2023 at 04:40 pm IST

From April 1, 2023 to May 31, 2023, the company has repurchased 235,100 shares, representing 0.94% for CAD 0.48 million. With this, the company has completed the repurchase of 1,259,100 shares, representing 4.95% for CAD 2.93 million under the buyback announced on May 25, 2022.

Latest news about Covalon Technologies Ltd.

Transcript : Covalon Technologies Ltd. - Shareholder/Analyst Call	07/03
Covalon Technologies Ltd. Reports Earnings Results for the First Quarter Ended December 31, 2023	28/02	CI
Covalon Technologies Reports Management Changes; Narrows Fiscal Q4 Loss, Revenue Grows; Up 17.8%	27/01	MT
Covalon Technologies Reports Management Changes; Narrows Fiscal Q4 Loss, Revenue Grows	26/01	MT
Covalon Technologies Narrows Fiscal Q4 Loss, Revenue Grows	26/01	MT
Covalon Technologies Ltd. Announces Interim Chief Financial Officer Changes	26/01	CI
Covalon Technologies Ltd. Announces Appointment of Kim Crooks as Senior Vice President - Operations	26/01	CI
Covalon Technologies Brief: Reporting 2023-Q4 revenue of $6.9 million, an increase of 28%, and net loss from continuing operations of $2.9 million, an improvement of $1.2 million	26/01	MT
Covalon Technologies Ltd. Reports Earnings Results for the Full Year Ended September 30, 2023	26/01	CI
Covalon Technologies Ltd. Reports Earnings Results for the Fourth Quarter Ended September 30, 2023	26/01	CI
Covalon Technologies Ltd. Announces Chief Executive Officer Changes	04/01	CI
Covalon Technologies Ltd. Announces Executive Changes	04/01	CI
Covalon Technologies Appoints MedTech Executive Brent Ashton as its New Chief Executive	04/01	MT
Covalon Technologies Brief: Appointing "Experienced" MedTech Executive Brent Ashton as New CEO	04/01	MT
Covalon Technologies Ltd. to Showcase Innovative Solutions at the Prestigious ANCC National Magnet Conference in Chicago	11/23/11	CI
Transcript : Covalon Technologies Ltd. - Special Call	27/23/27
Covalon Technologies Names Interim CEO; Begins Search for Permanent CEO	26/23/26	MT
Covalon Technologies Ltd. Announces Chief Executive Officer Changes	26/23/26	CI
Covalon Technologies Ltd. Appoints Joseph Cordiano as Independent Director	26/23/26	CI
Transcript : Covalon Technologies Ltd., Q3 2023 Earnings Call, Aug 16, 2023	16/23/16
Covalon Technologies Reports Total Q3 Revenue Increased 39% to $6.3 Million;	16/23/16	MT
Covalon Technologies Brief: Both net loss and net loss from continuing operations for the three months ended June 30, 2023 was $0.5 million or $0.02 per share	16/23/16	MT
Covalon Technologies Brief: Total revenue for the three months ended June 30, 2023 increased 39% to $6.3 million	16/23/16	MT
Tranche Update on Covalon Technologies Ltd.'s Equity Buyback Plan announced on May 25, 2022.	16/23/16	CI
Covalon Technologies Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023	16/23/16	CI

Chart Covalon Technologies Ltd.

Duration

Period

More charts

Company Profile

Covalon Technologies Ltd. is a patient-driven medical device company. Through a portfolio of patented technologies and solutions for advanced wound care, infection prevention, and medical device coatings, the Company offers gentler and more compassionate options for patients to heal with less infections, less pain, and better outcomes. Its solutions are designed for patients and made for care providers. It leverages its patented medical technology platforms and expertise in two ways: by developing products that are sold under Covalonâs name and by developing and commercializing medical products for other medical companies under development and license contracts. It provides a range of specialized medical devices, medical dressings and advanced medical technology designed for infection prevention, complex wound closure and perioperative care. Its perioperative care solutions provide antimicrobial protection of pre-operative skin, through postoperative incision care to scar prophylaxis.

Sector

Biotechnology & Medical Research

Calendar

27/05/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
COVALON TECHNOLOGIES LTD.	+2.83%	20.13M
MODERNA, INC.	+33.37%	49.46B
IQVIA HOLDINGS INC.	+1.55%	42.58B
LONZA GROUP AG	+49.11%	42.49B
CELLTRION, INC.	-4.22%	29.09B
ICON PUBLIC LIMITED COMPANY	+11.57%	26.61B
ALNYLAM PHARMACEUTICALS, INC.	-21.00%	18.64B
BIO-TECHNE CORPORATION	+7.36%	13.16B
MEDPACE HOLDINGS, INC.	+28.30%	12.55B
UNITED THERAPEUTICS CORPORATION	+23.80%	12.1B

Other Biotechnology & Medical Research